- Home
- RNGR vs GALT Comparison
RNGR vs GALT Comparison
Compare RNGR & GALT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RNGR
- GALT
- Stock Information
- Founded
- RNGR 2017
- GALT 2000
- Country
- RNGR United States
- GALT United States
- Employees
- RNGR N/A
- GALT N/A
- Industry
- RNGR Oilfield Services/Equipment
- GALT Biotechnology: Pharmaceutical Preparations
- Sector
- RNGR Energy
- GALT Health Care
- Exchange
- RNGR Nasdaq
- GALT Nasdaq
- Market Cap
- RNGR 279.8M
- GALT 232.3M
- IPO Year
- RNGR 2017
- GALT N/A
- Fundamental
- Price
- RNGR $13.64
- GALT $5.14
- Analyst Decision
- RNGR Hold
- GALT Strong Buy
- Analyst Count
- RNGR 1
- GALT 3
- Target Price
- RNGR $15.00
- GALT $6.00
- AVG Volume (30 Days)
- RNGR 150.6K
- GALT 313.3K
- Earning Date
- RNGR 11-10-2025
- GALT 11-12-2025
- Dividend Yield
- RNGR 1.76%
- GALT N/A
- EPS Growth
- RNGR 53.19
- GALT N/A
- EPS
- RNGR 0.99
- GALT N/A
- Revenue
- RNGR $571,900,000.00
- GALT N/A
- Revenue This Year
- RNGR N/A
- GALT N/A
- Revenue Next Year
- RNGR $6.75
- GALT N/A
- P/E Ratio
- RNGR $13.84
- GALT N/A
- Revenue Growth
- RNGR N/A
- GALT N/A
- 52 Week Low
- RNGR $10.56
- GALT $0.73
- 52 Week High
- RNGR $18.45
- GALT $6.55
- Technical
- Relative Strength Index (RSI)
- RNGR 53.04
- GALT 58.58
- Support Level
- RNGR $12.37
- GALT $4.77
- Resistance Level
- RNGR $14.25
- GALT $5.36
- Average True Range (ATR)
- RNGR 0.51
- GALT 0.28
- MACD
- RNGR 0.11
- GALT -0.00
- Stochastic Oscillator
- RNGR 70.60
- GALT 72.96
About RNGR Ranger Energy Services Inc.
Ranger Energy Services Inc is a provider of onshore high-specification (high-spec) well service rigs, wireline services, and additional processing solutions and ancillary services in the United States. It offers a range of well-site services to U.S. exploration and production (E&P) companies that are fundamental to establishing and enhancing the flow of oil and natural gas throughout the productive life of a well. The segments of the group are High Specification Rigs, Wireline Services and Processing Solutions, and Ancillary Services, of which key revenue is derived from the High Specification Rigs segment.
About GALT Galectin Therapeutics Inc.
Galectin Therapeutics Inc is a clinical-stage biopharmaceutical company. The company focuses on drug research and development to create new therapies for fibrotic disease, cancer, and selected other diseases. Its galectin-3 inhibitor is belapectin (GR-MD-02), which has been demonstrated in preclinical models to reverse liver fibrosis and cirrhosis.